Table 2

 Variables and distributions used in the model

EtanerceptAdalimumabInfliximabDMARDsDistribution
*Trial treatment (TT) recalculated to a reference placebo (RP) equal to (15, 8, 5)6 using the trial placebo (TP) and the formula: adjusted response  =  RP +{(1−RP)×([TT−TP]/[1−TP])};†recalculated to a reference placebo equal to (11, 5, 1)11 using same formula;‡median time receiving treatment  =  1.4 years. Assuming exponential decay (y = 1−e−±t);¶randomly sampled from leflunomide, ciclosporin or auranofin.
OPV, outpatient visits; CXR, chest x ray; CBC, complete blood count; LFT, liver function test; CMP, complete metabolic panel; SIP, subcutaneous injection procedure demonstration; INF, infusions.
% Response in combination dose finding trials (ACR20, ACR50, ACR70)*(66, 42, 19)11(67, 55, 27)6(47, 29, 12)13(37, 13, 0)14Dirichlet
% Response in combination dose finding and radiographic trials
> (ACR20, ACR50, ACR70)*
(57, 42, 24)7Dirichlet
% Response in monotherapy trials (ACR20, ACR50, ACR70)†(59, 40, 15)12(41, 19, 12)10Dirichlet
Withdrawal during 6 months0.08150.08150.12150.2732Beta
Adverse events during a period of 6 months
    Mild0.29150.29150.54150.3415Beta
    Moderate0.16150.16150.31150.2815Beta
    Serious0.07150.07150.1150.0615Beta
Monitoring and administration during the first 6 months12 OPV12 OPV8 OPV6 OPVFixed
1 CXR1 CXR1 CXR6 CBC
13 CBC13 CBC13 CBC6 LFT
1 LFT1 LFT1 LFT1 CMP
13 CMP13 CMP13 CMP
1 SIP1 SIP5 INF
Monitoring and administration during the subsequent 6 months6 OPV6 OPV2.5 OPV6 OPVFixed
6 CBC6 CBC6 CBC6 CBC
6 LFT6 LFT6 LFT6 LFT
3.5 INF1 CMP
Vial size (mg)2540100Random sample¶Fixed
Vial cost (SEK)1408.556184695Fixed
Dosage25 mg 2×wkly40 mg eow3 mg/kg every 8 weeksFixed